Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

A new generative AI tool developed by Mass General Brigham researchers, called RECTIFIER, was more efficient at screening and enrolling patients for a heart failure clinical trial than manual ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...